In Re: Vioxx Prod Liability

CourtCourt of Appeals for the Fifth Circuit
DecidedJanuary 31, 2013
Docket12-30311
StatusUnpublished

This text of In Re: Vioxx Prod Liability (In Re: Vioxx Prod Liability) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re: Vioxx Prod Liability, (5th Cir. 2013).

Opinion

Case: 12-30311 Document: 00512130826 Page: 1 Date Filed: 01/31/2013

IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT United States Court of Appeals Fifth Circuit

FILED January 31, 2013

No. 12-30311 Lyle W. Cayce Summary Calendar Clerk

In re: VIOXX PRODUCTS LIABILITY LITIGATION

EMMANUAL IWOBI,

Plaintiff - Appellant v.

MERCK AND COMPANY, INCORPORATED,

Defendant - Appellee

Appeal from the United States District Court for the Eastern District of Louisiana USDC No. 2:05-MD-1657 USDC No. 2:08-CV-1422

Before KING, CLEMENT, and HIGGINSON, Circuit Judges. PER CURIAM:* Plaintiff-Appellant Emmanual Iwobi appeals from the district court’s denial of his motion for reconsideration of a final order dismissing his action against Defendant-Appellee Merck Sharp & Dohme Corp. (Merck). Because

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5TH CIR. R. 47.5.4. Case: 12-30311 Document: 00512130826 Page: 2 Date Filed: 01/31/2013

No. 12-30311

Iwobi’s arguments either do not satisfy the standard for relief under Rule 60(b), or are not properly before this court, we AFFIRM the district court’s order. I. BACKGROUND In 2007, before Iwobi filed suit, Merck reached a Master Settlement Agreement (MSA) with negotiating counsel for plaintiffs in the multidistrict litigation (MDL) over Vioxx, a non-steroidal anti-inflammatory drug that was withdrawn from the market in 2004, and is alleged to cause heart attacks and other maladies. On the day the MSA was announced, the district court entered pretrial order (PTO) 29, which applied to all plaintiffs whose claims were transferred into the MDL on or after November 9, 2007. PTO 29, a Lone Pine order,1 imposed certain discovery requirements on such plaintiffs, including production of pharmacy and medical records, expert reports, and answers to Merck’s interrogatories. The productions required under PTO 29 are due within forty-five days of arrival in the MDL proceedings. A failure to produce within forty-five days could be cured within an additional thirty-day period after receiving a notice of deficiency from Merck. Failure to comply with the requirements after the cure period “shall lead to the dismissal of the claim with prejudice” absent showing of good cause. Iwobi’s case was governed by PTO 29 because it arrived in the MDL after November 9, 2007. Iwobi filed suit against Merck in Texas state court on January 15, 2008, alleging that he was injured from ingesting Vioxx. Merck removed the case to federal court, and then the case was transferred to the Eastern District as part of the MDL proceeding occurring therein.2

1 As we have explained, Lone Pine orders are “named for Lore v. Lone Pine Corp.,” and “are designed to handle the complex issues and potential burdens on defendants and the court in mass tort litigation.” In re Vioxx Prods. Liab. Litig. (Dier v. Merck & Co.), 388 F. App’x 391, 393 n.1 (5th Cir. 2010) (internal quotation marks and citation omitted). 2 The multidistrict proceedings were established in the district court in 2005. See generally Dier, 388 F. App’x at 393. In the instant case, the transfer to the Eastern District

2 Case: 12-30311 Document: 00512130826 Page: 3 Date Filed: 01/31/2013

Eight months later, after Iwobi had failed to comply with the discovery requirements of PTO 29, Merck filed a motion for order to show cause why his case should not be dismissed. The motion explained that: (1) Iwobi had not satisfied the requirements of PTO 29, and that (2) Merck had notified Iwobi’s counsel of the deficiency, but Iwobi had not cured it in the thirty-day period following receipt. Accordingly, Merck asked the court to dismiss Iwobi’s claims with prejudice. Iwobi did not reply to the motion, and on Feburary 3, 2009, the court dismissed his case with prejudice for failure to comply with the Lone Pine requirements of PTO 29. On March 29, 2010, Iwobi submitted a letter to the district court. Iwobi claimed that his attorney had told him that his case was on the right course, that he had been unable to contact his attorney for over a year, and that he recently learned that his action had been dismissed and that his attorney had been disbarred in February 2010. Accordingly, Iwobi asked the district court to reopen the case. The court ordered Merck to respond. After receiving Merck’s response and Iwobi’s reply, the district court denied Iwobi’s motion for reconsideration. The court reaffirmed the basis for dismissing Iwobi’s claims: “[d]espite several notices, no materials required by Pretrial Order 29 were ever produced in connection with Mr. Iwobi’s case, including no Lone Pine report.” The court then noted that Iwobi’s motion for reconsideration was filed more than a year after his case was dismissed, and therefore was governed by Federal Rule of Civil Procedure 60(b)(4)-(6). The district court further observed that Iwobi “was represented by counsel at all times prior to the dismissal of his case,” and that his attorney was not disbarred until more than a year after his case was dismissed. The court reasoned that, “[u]nder these circumstances, post-dismissal disciplinary action against a party’s

was made pursuant to orders issued by the Judicial Panel on Multidistrict Litigation.

3 Case: 12-30311 Document: 00512130826 Page: 4 Date Filed: 01/31/2013

attorney is not sufficient grounds to revisit the dismissal under Rule 60.” The court concluded by “express[ing] no opinion regarding Mr. Iwobi’s possible remedy against his former attorney.” Iwobi timely appealed. II. STANDARD OF REVIEW We review the denial of a Rule 60(b) motion for abuse of discretion. Bailey v. Cain, 609 F.3d 763, 767 (5th Cir. 2010). “‘A district court abuses its discretion if it bases its decision on an erroneous view of the law or on a clearly erroneous assessment of the evidence.’” Hesling v. CSX Transp., Inc., 396 F.3d 632, 638 (5th Cir. 2005) (quoting Kennedy v. Tex. Utils., 179 F.3d 258, 265 (5th Cir. 1999)). “It is not enough that the granting of relief might have been permissible, or even warranted—denial must have been so unwarranted as to constitute an abuse of discretion.” Crutcher v. Aetna Life Ins. Co., 746 F.2d 1076, 1082 (5th Cir. 1984). Our review is focused on the motion for reconsideration, and an appeal from the denial of such a motion “does not bring up the underlying judgment for review.” Bailey, 609 F.3d at 767. III. DISCUSSION Iwobi makes two arguments on appeal: (1) that the district court abused its discretion in denying his motion to reconsider, and (2) that dismissal with prejudice was an improperly harsh sanction for failure to comply with the district court’s Lone Pine orders. Iwobi’s first argument does not satisfy the “exceptional circumstances” standard justifying relief under Rule 60(b). His second argument is not properly before this court because it concerns the underlying judgment. Therefore, we find neither argument persuasive. We address each of these arguments in turn. A. Denial of the Motion to Reconsider Iwobi’s principal argument is that the district court abused its discretion in denying his motion to reconsider. Iwobi argues that dismissal of his case resulted from his counsel’s unresponsiveness and noncompliance with court

4 Case: 12-30311 Document: 00512130826 Page: 5 Date Filed: 01/31/2013

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Edward H. Bohlin Co., Inc. v. Banning Co., Inc.
6 F.3d 350 (Fifth Circuit, 1993)
Kennedy v. Texas Utilities
179 F.3d 258 (Fifth Circuit, 1999)
James v. Rice University
80 F. App'x 907 (Fifth Circuit, 2003)
Link v. Wabash Railroad
370 U.S. 626 (Supreme Court, 1962)
Bailey v. Cain
609 F.3d 763 (Fifth Circuit, 2010)
April Scarlott v. Nissan North America, Inc
769 F.3d 278 (Fifth Circuit, 2014)
Dier v. Merck & Co.
388 F. App'x 391 (Fifth Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
In Re: Vioxx Prod Liability, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-vioxx-prod-liability-ca5-2013.